vs
Side-by-side financial comparison of Sachem Capital Corp. (SACH) and Entrada Therapeutics, Inc. (TRDA). Click either name above to swap in a different company.
Entrada Therapeutics, Inc. is the larger business by last-quarter revenue ($20.6M vs $12.0M, roughly 1.7× Sachem Capital Corp.). Sachem Capital Corp. runs the higher net margin — 8.3% vs -84.4%, a 92.7% gap on every dollar of revenue. On growth, Sachem Capital Corp. posted the faster year-over-year revenue change (-18.8% vs -65.2%). Over the past eight quarters, Entrada Therapeutics, Inc.'s revenue compounded faster (6.4% CAGR vs -13.4%).
Sachem Capital Corp.SACHEarnings & Financial Report
Sachem Head Capital Management is an American value-oriented investment management firm based in New York City, managed by Scott Ferguson.
Entrada Therapeutics is a clinical-stage biotechnology firm developing transformative intracellular therapies for serious rare diseases and high-unmet-need disorders. Its pipeline covers neuromuscular, metabolic, and central nervous system segments, serving global patients via healthcare partnerships.
SACH vs TRDA — Head-to-Head
Income Statement — Q3 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.0M | $20.6M |
| Net Profit | $997.0K | $-17.3M |
| Gross Margin | — | — |
| Operating Margin | -3.1% | -106.0% |
| Net Margin | 8.3% | -84.4% |
| Revenue YoY | -18.8% | -65.2% |
| Net Profit YoY | 119.7% | -173.8% |
| EPS (diluted) | $0.00 | $-0.42 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | $12.0M | — | ||
| Q2 25 | $10.8M | — | ||
| Q1 25 | $11.4M | $20.6M | ||
| Q4 24 | $10.8M | $37.4M | ||
| Q3 24 | $14.8M | $19.6M | ||
| Q2 24 | $15.1M | $94.7M | ||
| Q1 24 | $16.8M | $59.1M | ||
| Q4 23 | $16.0M | $41.8M |
| Q3 25 | $997.0K | — | ||
| Q2 25 | $1.9M | — | ||
| Q1 25 | $904.0K | $-17.3M | ||
| Q4 24 | $-36.1M | $1.1M | ||
| Q3 24 | $-5.1M | $-14.0M | ||
| Q2 24 | $-3.1M | $55.0M | ||
| Q1 24 | $4.7M | $23.5M | ||
| Q4 23 | $-1.1M | $-9.5M |
| Q3 25 | -3.1% | — | ||
| Q2 25 | 9.9% | — | ||
| Q1 25 | 9.0% | -106.0% | ||
| Q4 24 | -131.1% | -15.7% | ||
| Q3 24 | -32.6% | -110.7% | ||
| Q2 24 | -20.6% | 56.4% | ||
| Q1 24 | 25.4% | 35.7% | ||
| Q4 23 | — | 11.7% |
| Q3 25 | 8.3% | — | ||
| Q2 25 | 17.5% | — | ||
| Q1 25 | 7.9% | -84.4% | ||
| Q4 24 | -335.6% | 3.0% | ||
| Q3 24 | -34.2% | -71.7% | ||
| Q2 24 | -20.2% | 58.1% | ||
| Q1 24 | 27.8% | 39.7% | ||
| Q4 23 | -6.9% | -22.8% |
| Q3 25 | $0.00 | — | ||
| Q2 25 | $0.02 | — | ||
| Q1 25 | $0.00 | $-0.42 | ||
| Q4 24 | $-0.79 | $-0.20 | ||
| Q3 24 | $-0.13 | $-0.35 | ||
| Q2 24 | $-0.09 | $1.55 | ||
| Q1 24 | $0.08 | $0.68 | ||
| Q4 23 | $-0.06 | $-0.23 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $12.6M | $67.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $175.6M | $417.3M |
| Total Assets | $484.4M | $486.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $12.6M | — | ||
| Q2 25 | $23.5M | — | ||
| Q1 25 | $25.8M | $67.8M | ||
| Q4 24 | $19.6M | $101.2M | ||
| Q3 24 | $7.4M | $78.0M | ||
| Q2 24 | $12.4M | $185.3M | ||
| Q1 24 | $56.8M | $68.4M | ||
| Q4 23 | $50.4M | $67.6M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | $230.2M | — | ||
| Q4 24 | $230.2M | — | ||
| Q3 24 | $264.7M | — | ||
| Q2 24 | $264.7M | — | ||
| Q1 24 | $288.4M | — | ||
| Q4 23 | $288.4M | — |
| Q3 25 | $175.6M | — | ||
| Q2 25 | $177.9M | — | ||
| Q1 25 | $179.3M | $417.3M | ||
| Q4 24 | $181.7M | $428.7M | ||
| Q3 24 | $220.6M | $422.4M | ||
| Q2 24 | $230.2M | $429.9M | ||
| Q1 24 | $237.4M | $269.4M | ||
| Q4 23 | $230.1M | $242.4M |
| Q3 25 | $484.4M | — | ||
| Q2 25 | $501.8M | — | ||
| Q1 25 | $491.4M | $486.5M | ||
| Q4 24 | $492.0M | $526.3M | ||
| Q3 24 | $555.5M | $554.6M | ||
| Q2 24 | $586.3M | $582.0M | ||
| Q1 24 | $626.5M | $510.8M | ||
| Q4 23 | $620.9M | $469.2M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 1.28× | — | ||
| Q4 24 | 1.27× | — | ||
| Q3 24 | 1.20× | — | ||
| Q2 24 | 1.15× | — | ||
| Q1 24 | 1.21× | — | ||
| Q4 23 | 1.25× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $4.9M | $-38.5M |
| Free Cash FlowOCF − Capex | — | $-39.7M |
| FCF MarginFCF / Revenue | — | -192.9% |
| Capex IntensityCapex / Revenue | — | 5.6% |
| Cash ConversionOCF / Net Profit | 4.95× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-58.0M |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | $4.9M | — | ||
| Q2 25 | $501.0K | — | ||
| Q1 25 | $191.0K | $-38.5M | ||
| Q4 24 | $12.9M | $-31.6M | ||
| Q3 24 | $2.3M | $-24.3M | ||
| Q2 24 | $7.0M | $39.8M | ||
| Q1 24 | $4.2M | $-25.5M | ||
| Q4 23 | $2.9M | $-4.0M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $-39.7M | ||
| Q4 24 | — | $-32.2M | ||
| Q3 24 | — | $-24.9M | ||
| Q2 24 | — | $38.8M | ||
| Q1 24 | — | $-26.4M | ||
| Q4 23 | — | $-5.0M |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -192.9% | ||
| Q4 24 | — | -86.2% | ||
| Q3 24 | — | -127.3% | ||
| Q2 24 | — | 41.0% | ||
| Q1 24 | — | -44.6% | ||
| Q4 23 | — | -11.9% |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.6% | ||
| Q4 24 | — | 1.7% | ||
| Q3 24 | — | 3.3% | ||
| Q2 24 | — | 1.1% | ||
| Q1 24 | — | 1.4% | ||
| Q4 23 | — | 2.3% |
| Q3 25 | 4.95× | — | ||
| Q2 25 | 0.27× | — | ||
| Q1 25 | 0.21× | — | ||
| Q4 24 | — | -27.94× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.72× | ||
| Q1 24 | 0.90× | -1.09× | ||
| Q4 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
